KYTX
Kyverna Therapeutics, Inc.
A clinical-stage biotech company engineering patients' own immune cells to fight autoimmune diseases such as lupus. Kyverna's lead therapy, KYV-101, is a CAR T-cell treatment that reprograms a patient's T cells to seek out and quiet the rogue immune cells driving the disease. Founded in 2018 in the San Francisco Bay Area, the company takes its name from the Greek word for "govern" or "guide," reflecting its aim to steer the immune system back into balance.
CUSIP: 501976104HealthcareUS1 holder
Total Value
$1.74M
Total Shares
70.0K
Net Share Change
+70.0K
Activity
1 buying
Investor
Value
Shares
Weight
Change
